Cilostazol Capsules

This product inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by endothelial cells. For patients with chronic arterial occlusion, the use of volume volumography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication.

Chemical name: 6-[4-(1-cyclohexyl-1H-pentyletetrazol(5)yl)butoxy]-3,4-dihydro-1H-quinolone (2).

This product is a capsule, and the contents are white powder and granules.

Improve ischemic symptoms caused by chronic arterial occlusive disease such as ulcers, limb pain, chills and intermittent claudication.

Adults: 100 mg bid.

The following symptoms may occasionally occur: allergic reactions such as rash, itching, palpitations, rapid pulse, fever, decreased blood pressure, headache, heaviness of the head, dizziness, insomnia, numbness, drowsiness, and abnormal digestive function.

Patients with bleeding such as hemophilia, capillary fragility, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, pregnant women or women who may become pregnant.

Precautions for children: The safety of children's use has not been established. Precautions for pregnancy and lactation: Women who are pregnant or may become pregnant. Precautions for the elderly: No such test has been conducted and there is no reliable reference document.

When used in combination with antiplatelet drugs and anticoagulants, the anticoagulant effect can be enhanced.

Sealed storage

50 mg

36 months

Zhejiang Weikang Pharmaceutical Co., Ltd.

• Founded in:

  2002-12-27

• Address:

  No. 15, Xinggong North Road, Jiangshan Economic Development Zone, Zhejiang Province

• Tax NO.:

  91330881753003855U

• Registered Funds:

  8.15 million yuan

• Website:

  Log in to view

• Email:

  Log in to view